Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: cardiovascular, cerebrovascular
- Who it enrolls
- age 18 Years to 99 Years; BMI ≥25 required; conditions: Type 2 Diabetes; Obesity
- Interventions
- 0.9% Sodium-chloride; Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min; Glucagon 12.5ng/kg/min and 0.9% saline; 0.9% Sodium-chloride; Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min; Glucagon 12.5ng/kg/min
- Conditions
- Type 2 Diabetes; Obesity
- Phase and size
- Phase 4 · 10 participants
- Dates
- Start 2022-01-18
Primary completion 2022-10-07 - Sponsor
- Cambridge University Hospitals NHS Foundation Trust (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Part A - Myocardial glucose uptakeComparison between scans over a maximum period of 16 weeks
- Part A - Global longitudinal strain / global circumferential strain / global radial strainComparison between scans over a maximum period of 16 weeks
- Part A - Ejection fractionComparison between scans over a maximum period of 16 weeks
- Part A - Stroke volumeComparison between scans over a maximum period of 16 weeks
- Part A - Cardiac outputComparison between scans over a maximum period of 16 weeks
- Part B - Changes in phosphocreatine/adenosine (PCr/ATP) radioComparison between scans over a maximum period of 16 weeks
- Part B - Changes in absolute concentrations of PCr and ATP defined by AHA 17- segment territory as a measure of cardiac energy status (determined by 31P-MRS)Comparison between scans over a maximum period of 16 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Written informed consent to participate * Aged \>18 years * Clinical diagnosis of T2DM, either diet controlled or treated with metformin (to be withheld on the morning of the imaging visit) * BMI ≥25kg/m2 * Current non-smoker Exclusion Criteria: * Females of childbearing potential (Part A only) / current pregnancy (all parts) * Sustained Hypertension (sustained BP \>160/100mmHg) or hypotension (systolic BP below 90 mmHg) * Clinically significant heart disease * Implanted heart pacemaker or implantable cardioverter defibrillator (ICD) * Known active malignancy other than skin cancer * Known renal failure (creatinine \>150µmol/L) * Known type one diabetes mellitus / known or clinically suspected diagnosis of a monogenic form of diabetes * Poorly controlled blood glucose * Current daily use of anti-diabetic medication including Insulin, GLP-1 based agonists, DPP4i or any other medication known to interact with either of the study drugs (exenatide or glucagon) * Current involvement in the active treatment phase of other research studies, (excluding observational/non-interventional). * Contraindication for MRI/PET scan, i.e. any reason which precludes MRI imaging according to local policy (ie internal pacemaker/defibrillator, metal fragments, claustrophobia) * Participation in research studies in the last 3 years involving radiation (if the effective dose exceeded 10mSv). This does not include any diagnostic or therapeutic exposures which were clinically justified. * Any other clinical reason which may preclude entry in the opinion of the investigator
03Change log
Registry changes
No changes recorded since the trial was added.